| Schedule of segment and corporate information |
Segment and corporate information in € K | | | | | | | | | | | | | | | | | Care | | Value- | | Care | | Total | | Inter-segment | | | | | | | Delivery | | Based Care | | Enablement | | Segment | | eliminations | | Corporate | | Total | Three months ended June 30, 2026 | | | | | | | | | | | | | | | Revenue from healthcare services(1) | | 3,234,409 | | 17,765 | | — | | 3,252,174 | | — | | — | | 3,252,174 | Revenue from healthcare products(1) | | 105,639 | | — | | 959,446 | | 1,065,085 | | — | | — | | 1,065,085 | Revenue from contracts with customers(1) | | 3,340,048 | | 17,765 | | 959,446 | | 4,317,259 | | — | | — | | 4,317,259 | Revenue from insurance contracts(1) | | — | | 518,372 | | — | | 518,372 | | — | | — | | 518,372 | Revenue from lease contracts(1) | | — | | — | | 24,935 | | 24,935 | | — | | — | | 24,935 | Revenue from external customers | | 3,340,048 | | 536,137 | | 984,381 | | 4,860,566 | | — | | — | | 4,860,566 | Inter-segment revenue | | 138,266 | | — | | 386,679 | | 524,945 | | (524,945) | | — | | — | Revenue | | 3,478,314 | | 536,137 | | 1,371,060 | | 5,385,511 | | (524,945) | | — | | 4,860,566 | Costs of revenue | | (2,594,852) | | (495,322) | | (946,513) | | (4,036,687) | | 485,775 | | 328 | | (3,550,584) | Research and development | | — | | — | | (39,709) | | (39,709) | | — | | 79 | | (39,630) | Operating income (loss) | | 434,946 | | 17,330 | | 98,617 | | 550,893 | | (39,170) | | (45,868) | | 465,855 | Interest | | | | | | | | | | | | | | (82,856) | Income before income taxes | | | | | | | | | | | | | | 382,999 | Depreciation and amortization | | (230,694) | | (197) | | (120,453) | | (351,344) | | 9,877 | | (15,692) | | (357,159) | Impairment loss | | (5,531) | | — | | (312) | | (5,843) | | — | | (110) | | (5,953) | Income (loss) from equity method investees | | (41,256) | | — | | — | | (41,256) | | — | | — | | (41,256) | Additions of property, plant and equipment, intangible assets and right-of-use assets(1) | | 251,534 | | 103 | | 112,136 | | 363,773 | | (48,521) | | 34,994 | | 350,246 | | | | | | | | | | | | | | | | Three months ended June 30, 2025 | | | | | | | | | | | | | | | Revenue from healthcare services(1) | | 3,207,936 | | 17,416 | | — | | 3,225,352 | | — | | — | | 3,225,352 | Revenue from healthcare products(1)(2) | | 54,871 | | — | | 1,003,476 | | 1,058,347 | | — | | — | | 1,058,347 | Revenue from contracts with customers(1) | | 3,262,807 | | 17,416 | | 1,003,476 | | 4,283,699 | | — | | — | | 4,283,699 | Revenue from insurance contracts(1) | | — | | 488,279 | | — | | 488,279 | | — | | — | | 488,279 | Revenue from lease contracts(1) | | — | | — | | 19,735 | | 19,735 | | — | | — | | 19,735 | Revenue from external customers | | 3,262,807 | | 505,695 | | 1,023,211 | | 4,791,713 | | — | | — | | 4,791,713 | Inter-segment revenue(2) | | 117,875 | | — | | 324,632 | | 442,507 | | (442,507) | | — | | — | Revenue | | 3,380,682 | | 505,695 | | 1,347,843 | | 5,234,220 | | (442,507) | | — | | 4,791,713 | Costs of revenue(2) | | (2,603,301) | | (486,685) | | (923,025) | | (4,013,011) | | 434,125 | | 1,534 | | (3,577,352) | Research and development | | — | | — | | (38,116) | | (38,116) | | — | | — | | (38,116) | Operating income (loss)(2) | | 346,402 | | (8,842) | | 89,023 | | 426,583 | | (8,382) | | 7,082 | | 425,283 | Interest | | | | | | | | | | | | | | (74,729) | Income before income taxes | | | | | | | | | | | | | | 350,554 | Depreciation and amortization | | (243,716) | | (1,435) | | (109,328) | | (354,479) | | 9,406 | | (16,958) | | (362,031) | Impairment loss | | (10,003) | | 82 | | (3,283) | | (13,204) | | — | | — | | (13,204) | Income (loss) from equity method investees | | 45,175 | | — | | — | | 45,175 | | — | | — | | 45,175 | Additions of property, plant and equipment, intangible assets and right-of-use assets(1) | | 177,749 | | 91 | | 113,538 | | 291,378 | | (10,942) | | 6,558 | | 286,994 |
| (1) | These line items are included to comply with requirements under IFRS 8 and IFRS 15 or are provided on a voluntary basis, but not included in the information regularly reviewed by the chief operating decision maker. |
| (2) | For amounts not reclassified related to the shift of the global pharmaceutical business from Care Enablement to Care Delivery, see discussion above. |
| | | | | | | | | | | | | | | Segment and corporate information (continued) | in € K | | | | | | | | | | | | | | | | | | | Value-Based | | Care | | Total | | Inter-segment | | | | | | | Care Delivery | | Care | | Enablement | | Segment | | eliminations | | Corporate | | Total | Six months ended June 30, 2026 | | | | | | | | | | | | | | | Revenue from healthcare services(1) | | 6,335,565 | | 61,116 | | — | | 6,396,681 | | — | | — | | 6,396,681 | Revenue from healthcare products(1) | | 177,172 | | — | | 1,889,800 | | 2,066,972 | | — | | — | | 2,066,972 | Revenue from contracts with customers(1) | | 6,512,737 | | 61,116 | | 1,889,800 | | 8,463,653 | | — | | — | | 8,463,653 | Revenue from insurance contracts(1) | | — | | 965,391 | | — | | 965,391 | | — | | — | | 965,391 | Revenue from lease contracts(1) | | — | | — | | 43,669 | | 43,669 | | — | | — | | 43,669 | Revenue from external customers | | 6,512,737 | | 1,026,507 | | 1,933,469 | | 9,472,713 | | — | | — | | 9,472,713 | Inter-segment revenue | | 259,145 | | — | | 736,584 | | 995,729 | | (995,729) | | — | | — | Revenue | | 6,771,882 | | 1,026,507 | | 2,670,053 | | 10,468,442 | | (995,729) | | — | | 9,472,713 | Costs of revenue | | (5,141,438) | | (946,708) | | (1,832,591) | | (7,920,737) | | 935,108 | | 2,390 | | (6,983,239) | Research and development | | — | | — | | (77,939) | | (77,939) | | — | | — | | (77,939) | Operating income (loss) | | 706,134 | | 6,292 | | 185,886 | | 898,312 | | (60,621) | | (85,641) | | 752,050 | Interest | | | | | | | | | | | | | | (161,535) | Income before income taxes | | | | | | | | | | | | | | 590,515 | Depreciation and amortization | | (463,131) | | (855) | | (237,826) | | (701,812) | | 19,927 | | (29,175) | | (711,060) | Impairment loss | | (75,400) | | — | | (4,263) | | (79,663) | | — | | (35,330) | | (114,993) | Income (loss) from equity method investees | | 66 | | — | | — | | 66 | | — | | — | | 66 | Total assets(1) | | 42,076,323 | | 616,408 | | 14,598,488 | | 57,291,219 | | (38,114,002) | | 12,116,023 | | 31,293,240 | thereof investment in equity method investees(1) | | 660,694 | | — | | — | | 660,694 | | — | | — | | 660,694 | Additions of property, plant and equipment, intangible assets and right-of-use assets(1) | | 454,200 | | 141 | | 230,377 | | 684,718 | | (76,019) | | 59,365 | | 668,064 | | | | | | | | | | | | | | | | Six months ended June 30, 2025 | | | | | | | | | | | | | | | Revenue from healthcare services(1) | | 6,458,118 | | 43,547 | | — | | 6,501,665 | | — | | — | | 6,501,665 | Revenue from healthcare products(1)(2) | | 132,433 | | — | | 2,005,105 | | 2,137,538 | | — | | — | | 2,137,538 | Revenue from contracts with customers(1) | | 6,590,551 | | 43,547 | | 2,005,105 | | 8,639,203 | | — | | — | | 8,639,203 | Revenue from insurance contracts(1) | | — | | 991,639 | | — | | 991,639 | | — | | — | | 991,639 | Revenue from lease contracts(1) | | — | | — | | 42,325 | | 42,325 | | — | | — | | 42,325 | Revenue from external customers | | 6,590,551 | | 1,035,186 | | 2,047,430 | | 9,673,167 | | — | | — | | 9,673,167 | Inter-segment revenue(2) | | 236,959 | | — | | 667,345 | | 904,304 | | (904,304) | | — | | — | Revenue | | 6,827,510 | | 1,035,186 | | 2,714,775 | | 10,577,471 | | (904,304) | | — | | 9,673,167 | Costs of revenue(2) | | (5,342,930) | | (979,314) | | (1,845,280) | | (8,167,524) | | 890,606 | | 2,090 | | (7,274,828) | Research and development | | — | | — | | (81,598) | | (81,598) | | — | | — | | (81,598) | Operating income (loss)(2) | | 666,399 | | (5,593) | | 183,324 | | 844,130 | | (13,699) | | (73,758) | | 756,673 | Interest | | | | | | | | | | | | | | (155,466) | Income before income taxes | | | | | | | | | | | | | | 601,207 | Depreciation and amortization | | (504,322) | | (2,676) | | (223,874) | | (730,872) | | 20,242 | | (33,998) | | (744,628) | Impairment loss | | (17,079) | | (2,192) | | (5,699) | | (24,970) | | — | | — | | (24,970) | Income (loss) from equity method investees | | 93,008 | | — | | — | | 93,008 | | — | | — | | 93,008 | Total assets(1) | | 39,706,254 | | 590,177 | | 14,001,499 | | 54,297,930 | | (34,403,317) | | 11,396,571 | | 31,291,184 | thereof investment in equity method investees(1) | | 710,728 | | — | | — | | 710,728 | | — | | — | | 710,728 | Additions of property, plant and equipment, intangible assets and right-of-use assets(1) | | 387,485 | | 198 | | 225,823 | | 613,506 | | (20,779) | | 11,975 | | 604,702 |
| (1) | These line items are included to comply with requirements under IFRS 8 and IFRS 15 or are provided on a voluntary basis, but not included in the information regularly reviewed by the chief operating decision maker. |
| (2) | For amounts not reclassified related to the shift of the global pharmaceutical business from Care Enablement to Care Delivery, see discussion above. |
|